WWM
ALXN

Willingdon Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Willingdon Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3
Closed – – 560
2019
Q3 		$0 Buy
+3
New +$338 ﹤0.01% 551

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Willingdon Wealth Management's ALXN Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 3 shares.

Willingdon Wealth Management first reported a position in ALXN in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 3 Alexion Pharmaceuticals shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Alexion Pharmaceuticals position peaked at $0 in Q3 2019.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.